Skip to main content
Back to Trials
NCT07798323Recruiting

Noninvasive Imaging Biomarkers of Treatable Macrovascular Disease in Age-related Macular Degeneration.

Scott Raymond

Start Date

9/1/2026

Completion Date

12/1/2028

Summary

The purpose of this prospective study is to investigate whether ophthalmic artery stenosis (narrowing of the ophthalmic artery) contributes to the development and progression of geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD).

Eligibility Criteria

Age Range: 50 years to 80 years

Inclusion Criteria: * 50-80 years of age * All genders * Asymmetric dry AMD with geographic atrophy in at least one eye and reduced disease severity in the other eye according to International Classification of Disease (ICD) codes * Treated at the Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio Exclusion Criteria: * Poor image quality that limits quantification * GA extending beyond the borders of the SDOCT field of view. * Bilateral symmetric geographic atrophy. * Diagnosis of wet AMD. * Any retinal fluid at baseline. * Other concurrent retinal diseases * Vitreoretinal surgery. * Allergy to iodinated contrast agents. * Chronic kidney disease with eGFR \< 60

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Macular Degeneration

Locations

Cleveland Clinic

Cleveland, Ohio 44195

United States